Last reviewed · How we verify
IOBENGUANE
At a glance
| Generic name | IOBENGUANE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1994 |
Approved indications
Common side effects
- Injection site hemorrhage
- Headache
- Flushing
- Dizziness
- Rash
- Pruritus
Serious adverse events
- Hypersensitivity reactions
Key clinical trials
- Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma (PHASE2)
- Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma (PHASE2)
- Next Generation Personalized Neuroblastoma Therapy (PHASE1)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin (PHASE1)
- MIBG for Refractory Neuroblastoma and Pheochromocytoma (NA)
- NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab (PHASE2)
- Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IOBENGUANE CI brief — competitive landscape report
- IOBENGUANE updates RSS · CI watch RSS